ArticleFrontiers in immunology2025
Integration of multi-omics and machine learning strategies identifies immune related candidate biomarkers in inflammation-associated hypertrophic cardiomyopathy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Knowledge mapping of targeted therapy for hypertrophic cardiomyopathy: A bibliometric analysis of myosin inhibitor research.Medicine · 2026Article
- An interpretable machine learning model for biomarker identification and diagnostic nomogram development in hypo-productive thrombocytopenia.Scientific reports · 2026Article
- Identification of Centrosome Duplication-Related Biomarkers in Hypertrophic Cardiomyopathy Through Integrative Multi-Omics, Single-Cell Transcriptomics, and Experimental Validation.Journal of the American Heart Association · 2026Article
- VCPIP1 drives diabetic cardiomyopathy by deubiquitinating AMPKγ1 and preventing AMPKα-γ subunit assembly in cardiomyocytes.Signal transduction and targeted therapy · 2026Article
- Integrated bioinformatics and mendelian randomization reveal a six-gene diagnostic signature and key role of CYP26B1 in sarcopenia.Frontiers in molecular biosciences · 2026Article
- Non-coding RNAs in programmed cell death regulation in melanoma: mechanisms and therapeutic insights.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease frequently leading to heart failure. Although sarcomeric gene mutations are known, they only account for a subset of cases. The role of immune dysregulation in HCM progression has gained increasing attention, necessitating the exploration of immune-related biomarkers and therapeutic targets. This study integrates Mendelian randomization (MR), transcriptomics, machine learning, and experimental validation to investigate the immune mechanisms underlying HCM. Methods: We analyzed three transcriptomic datasets from the GEO database (210 healthy controls, 152 HCM patients) and identified differentially expressed genes (DEGs) using the R package limma. MR analysis was performed on 19,942 expression quantitative trait loci (eQTLs) and HCM cases using the TwoSampleMR package. Machine learning (10 algorithms) was employed to construct diagnostic models, and SHAP analysis was applied to assess key gene contributions. Functional enrichment was performed with clusterProfiler, diagnostic performance was evaluated via ROC curves, and immune cell infiltration was analyzed using CIBERSORT. A competing endogenous RNA (ceRNA) network was constructed, and drug targets were predicted via the DGIdb database. Key gene expression was validated by qPCR. Results: We identified 472 DEGs and 205 HCM-associated loci, narrowing down to seven key genes: RNF165, SNCA, SRGN, MARCO, STEAP4, SIGLEC9, and TKT. These genes were enriched in immune-related pathways (e.g., cytokine activity, leukocyte migration, JAK-STAT signaling). The Random Forest model exhibited the highest diagnostic performance (AUC: 0.939), with SHAP analysis revealing MARCO as the top contributor. Gene expression was associated with immune cell infiltration: HCM samples showed increased CD4+ T cells and M0 macrophages but decreased M2 macrophages and neutrophils. The ceRNA network comprised 5 mRNAs, 40 miRNAs, and 152 lncRNAs. SRGN and SNCA were identified as potential targets for heparin and 33 other drugs, respectively. qRT-PCR performed on a small number of myocardial samples supported expression trends of the identified genes, in line with transcriptomic analysis. Conclusion: This study reveals immune-related mechanistic biomarkers and potential therapeutic targets in HCM, highlighting the role of immune dysregulation in disease progression. Machine learning and SHAP analysis improved diagnostic model interpretability, providing a basis for future development of non-invasive diagnostic tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.